Subscribe to Supplier
Subscribe to Supplier
HAPILA GmbH News Releases
Find the latest News from HAPILA GmbH
HAPILA and ATHANA alliance receive funding for nanoparticle antifungal program
Wednesday 13th September 2023
Learn More >
HAPILA’s co-developed anti-TB agent BTZ-043 named ‘Drug of the Year’
Friday 8th September 2023
Learn More >
HAPILA shows advanced API development capabilities at Chemspec Europe 2023
Thursday 11th May 2023
Learn More >
HAPILA commences cGMP pilot scale manufacture of anti-TB API BTZ-043
Wednesday 16th November 2022
Learn More >
CEP Revision extends HAPILA Estriol API retest period to 60 months
Thursday 23rd June 2022
Learn More >
HAPILA extends co-operation with Transo-Pharm to meet Estriol demand
Tuesday 8th March 2022
Learn More >
Authorities confirm cGMP status for HAPILA’s Estriol estrogen API manufacturing
Thursday 17th February 2022
Learn More >
HAPILA starts optimized pilot scale production of BTZ-043 anti TB agent
Thursday 13th January 2022
Learn More >
HAPILA reaching completion of design for new GMP production plant for APIs
Thursday 26th August 2021
Learn More >